Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection
10.1016/j.apjtm.2017.06.012
- Author:
Somsri WIWANITKIT
1
;
Viroj WIWANITKIT
2
;
Viroj WIWANITKIT
3
;
Viroj WIWANITKIT
4
;
Viroj WIWANITKIT
5
Author Information
1. Wiwanitkit House
2. Hainan Medical University
3. Dr DY Patil University
4. Faculty of Medicine, University of Nis
5. Joseph Ayobabalola University
- Publication Type:Journal Article
- Keywords:
Dosage;
Inhibiting;
Sofosbuvir;
Zika virus
- From:
Asian Pacific Journal of Tropical Medicine
2017;10(6):612-613
- CountryChina
- Language:Chinese
-
Abstract:
Sofosbuvir is a new antiviral drug that has been recommended for management of hepatitis C virus (HCV) for a few years. New researches support that sofosbuvir might be useful for the management of Zika virus infection. Based on the pharmacological activity, inhibiting the HCV RNA-dependent RNA polymerase (RdRp or NS5 protein), sofosbuvir is proposed for its effectiveness against Zika virus infection. Here, the authors used a mathematical modelling theoretical approach to predict the expected dosage of sofosbuvir for inhibiting Zika virus infection. Based on the modeling study, if sofosbuvir is assigned for management of Zika virus infection, doubled dosage of the present dosage for hepatitis C management is recommended.
